EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A CRISPR-based mitochondrial gene therapy tool derived by engineering guide RNAs

Ying Wang, Xinwan Su, Yu Chen, Yijian Chen, Chengyu Shi, Fangzhou Liu, Yuqi Ye, Panyi Sun, Manman Tan, Meng Yu, Ya Wang, Shanshan Xie und 9 weitere

Cell Reports · 2026-02 · 45 (2) · 116958

DOI: 10.1016/j.celrep.2026.116958 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2026-02. Verfasst von Ying Wang und 20 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China; Department of Respiratory and Critical Care Medicine, Center for RNA…. Hauptthemen laut MEDLINE: RNA, Guide, CRISPR-Cas Systems, Mitochondria, CRISPR-Cas Systems, Genetic Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province, National Science Fund for Distinguished Young Scholars, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mitochondrial genetic diseases arise from mitochondrial DNA (mtDNA) defects, which gene therapy tools may rectify. However, delivering single-guide RNAs (sgRNAs) into mitochondria remains a challenge limiting CRISPR-mediated mtDNA therapy. Here, through network analysis of mitochondrion-localized long noncoding RNAs (lncRNAs) and RNA-binding proteins (RBPs), we found that lncRNA RP11-46H11.3 translocates into mitochondria via binding mitochondria-associated RBPs using its key RNA recognition motifs (RRMs); its derived 30 nt ST2-RNA mitochondrial targeting sequence (RMTS) showed the highest mitochondrial localization efficiency. We engineered the RMTS-CRISPR tool by fusing ST2-RMTS to sgRNA, verifying its ability to target and cleave mtDNA. Strikingly, our results demonstrated that RMTS-CRISPR could achieve heteroplasmic mtDNA shifting efficiencies of up to 26.37% in m.3243A>G mutant cell models and 26.79% in vivo, offering a technological approach for the correction of heterogeneous mtDNA mutations. Taken together, our findings reveal a CRISPR-based mitochondrial gene intervention strategy that may have applications in mitochondrial disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Guide, CRISPR-Cas SystemsMitochondriaCRISPR-Cas SystemsGenetic TherapyDNA, MitochondrialHumansAnimals

Stichwörter der Autor:innen

CP: genomicsCRISPR-Cas systemRNA recognition motifmitochondrial DNAmitochondrial disorderorganelle-associated RNA

Substanzen

RNA, Guide, CRISPR-Cas SystemsDNA, Mitochondrial

Autor:innen und Institutionen

  • College of Life Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China; Department of Respiratory and Critical Care Medicine, Center for RNA Medicine, the Fourth Affiliated Hospital of School of Medicine, and I…
  • Key Laboratory of Laboratory Medicine, Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang…
  • Cancer Center, Zhejiang University, Hangzhou 310058, Zhejiang, China; Department of Cell Biology and Program in Molecular Cell Biology, Zhejiang University School of Medicine, Hangzhou 310058, Zhejiang, China; Departmen…
  • Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Haining 314400, Zhejiang, China.
  • College of Life Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China.
  • Center for Metabolism Research, the Fourth Affiliated Hospital of Zhejiang University School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu 322000, Zhejian…

Förderung

  • Natural Science Foundation of Zhejiang Province
  • National Science Fund for Distinguished Young Scholars
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Fundamental Research Funds for the Central Universities
  • National Science and Technology Major Project
  • Guangzhou Medical University
  • Wenzhou Medical University

Zitieren

APA

Wang, Y., Su, X., Chen, Y., Chen, Y., Shi, C., Liu, F., Ye, Y., Sun, P., Tan, M., Yu, M., Wang, Y., Xie, S., Liu, J., Yan, Q., Sun, Q., Neculai, D., Liu, W., Shao, J., Liu, Y., …, & Lin, A. (2026). A CRISPR-based mitochondrial gene therapy tool derived by engineering guide RNAs. Cell Reports, 45(2), 116958. https://doi.org/10.1016/j.celrep.2026.116958

Vancouver

Wang Y, Su X, Chen Y, Chen Y, Shi C, Liu F, et al. A CRISPR-based mitochondrial gene therapy tool derived by engineering guide RNAs. Cell Reports. 2026;45(2):116958. doi:10.1016/j.celrep.2026.116958

BibTeX
@article{Wang2026,
  author = {Wang, Ying and Su, Xinwan and Chen, Yu and Chen, Yijian and Shi, Chengyu and Liu, Fangzhou and Ye, Yuqi and Sun, Panyi and Tan, Manman and Yu, Meng and Wang, Ya and Xie, Shanshan and Liu, Jian and Yan, Qingfeng and Sun, Qiming and Neculai, Dante and Liu, Wei and Shao, Jianzhong and Liu, Yang and Lin, Weiqiang and Lin, Aifu},
  title = {A CRISPR-based mitochondrial gene therapy tool derived by engineering guide RNAs},
  journal = {Cell Reports},
  year = {2026},
  volume = {45},
  number = {2},
  pages = {116958},
  doi = {10.1016/j.celrep.2026.116958}
}
Kostenlos starten →